The Korean journal of internal medicine

  • 제26권4호
  • /
  • Pages.400-402
  • /
  • 2011
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Is the Low-Thalidomide Dose MPT Regimen Beneficial?

  • Min, Chang-Ki (Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea School of Medicine)
  • 발행 : 2011.12.01
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107-3114. https://doi.org/10.1182/blood-2008-04-149427
  2. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced- intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209-1218. https://doi.org/10.1016/S0140-6736(07)61537-2
  3. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009;27:3664-3670. https://doi.org/10.1200/JCO.2008.21.0948
  4. Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010;116:1405-1412. https://doi.org/10.1182/blood-2009-08-237974
  5. Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010;28:3160-3166. https://doi.org/10.1200/JCO.2009.26.1610
  6. Sze DM, Brown R, Yang S, Ho PJ, Gibson J, Joshua D. The use of thalidomide in myeloma therapy as an effective anticancer drug. Curr Cancer Drug Targets 2006;6:325-331. https://doi.org/10.2174/156800906777441762
  7. Patrick HE, Bowcock SJ. Ultra low dose thalidomide in myeloma revisited. Br J Haematol 2010;150:232-234.
  8. Chang HJ, Lee JH, Do YR, et al. A combination of melphalan, prednisone, and 50 mg thalidomide treatment in non-transplant- candidate patients with newly diagnosed multiple myeloma. Korean J Intern Med 2011;26:403-409. https://doi.org/10.3904/kjim.2011.26.4.403
  9. Cherian G, Thomas DW, Rule SA. The efficacy of low dose thalidomide in refractory/relapsed myeloma: a retrospective audit. Leuk Lymphoma 2006;47:2409-2411. https://doi.org/10.1080/10428190600879813
  10. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008;111:3968- 3977. https://doi.org/10.1182/blood-2007-10-117457